Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Sorry, there are no financial reports available yet.
Investor presentations
Results: PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
Investor Presentation Conference Call 6th July, 2020
Investor Presentation Jefferies Virtual Healthcare Conference June 3rd, 2020
JP Morgan Healthcare Conference, San Francisco, 15th January 2020
Linzagolix Phase 3 PRIMROSE 2 Trial Results
Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019
Cantor Global Healthcare Conference October 4 2019
The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019
Press Releases
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023
press release
March 15, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 –…
Read moreObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
press release
March 13, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 –…
Read moreObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
press release
February 24, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 –…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2022
May 18, 2022
ObsEva Annual General Meeting 2021
May 28, 2021
Upcoming Events
Stock Information
Latest Press Release
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 –…
Read moreInvestor Contact
Media Contact
Contacts
ObsEva Switzerland Office
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840
Sign up for news
